During a live event, Daniel M. Geynisman, MD, and participants discussed their answers to a poll on which combination to use ...

During a live event, Matthew Galsky, MD, discussed adjuvant nivolumab in muscle-invasive bladder cancer and the benefit in ...

Renal cell carcinoma (RCC) is recognized as an immunogenic tumor, yet tumor-infiltrating lymphocytes often exhibit diminished effector function. However, the mechanisms underlying reduced T and NK ...

Results from the PHENIX-I trial support skipping pelvic lymphadenectomy in women with early cervical cancer who have a negative sentinel lymph node biopsy. Omitting pelvic lymphadenectomy in these ...

model to distinguish between low- and high-grade clear cell renal cell carcinoma (ccRCC). Conclusion: The MAD diffusion model shows promise as a non-invasive imaging tool for distinguishing between ...

Background: Characterized by a poor prognosis and survivability, head and neck squamous cell carcinoma (HNSCC) is an aggressive neoplastic condition with a propensity for recurrence where the ...

Politicians love a lofty goal, but the enemy at the time was barely understood, let alone close to being conquered. Fifty three years on, enormous strides have been made in understanding cancer ...

Cabozantinib is an oral multikinase inhibitor approved for treatment in metastatic renal cell carcinoma (RCC). We conducted a phase 2, nonrandomized, single-arm clinical trial (NCT04022343) of ...